Investment Counsel Company of Nevada’s ARK Genomic Revolution ETF ARKG Stock Holding History

Investment Counsel Company of Nevada’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.6K	Hold	728	–	–	0.06%	65
2026 Q1	$19.2K	Hold	728	–	–	0.04%	67
2025 Q4	$21.1K	Hold	728	–	–	0.05%	66
2025 Q3	$20.2K	Hold	728	–	–	0.04%	57
2025 Q2	$17.7K	Hold	728	–	–	0.04%	59
2025 Q1	$15.1K	Hold	728	–	–	0.03%	53
2024 Q4	$17.1K	Buy	+728	New	+$17.9K	0.04%	41

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $1.02B AUM 31.16% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

MFPI

Midwest Financial Partners Investments St. Cloud, Minnesota $241M AUM

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

CIC

Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return

Investment Counsel Company of Nevada's ARKG Position: Q2 2026 in Review

Investment Counsel Company of Nevada held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 728 shares worth $30.6K. The position accounts for 0.06% of the portfolio, ranked #65.

Investment Counsel Company of Nevada first reported a position in ARKG in Q4 2024 and has held it in 7 quarters since. 193 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Investment Counsel Company of Nevada held 728 shares of ARK Genomic Revolution ETF worth $30.6K as of Q2 2026.
Investment Counsel Company of Nevada left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up 0.06% of Investment Counsel Company of Nevada's portfolio in Q2 2026, its #65 holding.
Investment Counsel Company of Nevada first reported a position in ARK Genomic Revolution ETF in Q4 2024 and has held it in 7 quarters since.
193 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Investment Counsel Company of Nevada's 13F filing for Q2 2026, filed 10 Aug 2026.